Study Summary
This trial will explore whether exercise can help protect the hearts of breast cancer patients receiving chemotherapy that is known to damage heart health.
Eligible Conditions
- Breast Cancer
- Cardiovascular Disease
- Cardiotoxicity
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: Outcome will be assessed at baseline (week 0), post-intervention (week-13) and 6 months after the completion of the intervention.
Month 6
Change in Left Ventricular (LV) Function
Month 6
Change in Aerobic Fitness
Change in Blood biomarkers
Change in Fatigue
Change in Functional Assessment for Cancer Therapy
Month 6
Change in Cardiac Electrical Activity
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Control
1 of 2
Exercise
1 of 2
Active Control
Experimental Treatment
100 Total Participants · 2 Treatment Groups
Primary Treatment: Aerobic exercise · No Placebo Group · N/A
Exercise
Behavioral
Experimental Group · 1 Intervention: Aerobic exercise · Intervention Types: BehavioralControlNoIntervention Group · 1 Intervention: Control · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aerobic exercise
2000
Completed Phase 2
~1080
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: outcome will be assessed at baseline (week 0), post-intervention (week-13) and 6 months after the completion of the intervention.
Who is running the clinical trial?
Canadian Cancer Society (CCS)OTHER
71 Previous Clinical Trials
30,799 Total Patients Enrolled
5 Trials studying Breast Cancer
370 Patients Enrolled for Breast Cancer
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,233 Previous Clinical Trials
24,676,552 Total Patients Enrolled
9 Trials studying Breast Cancer
4,179 Patients Enrolled for Breast Cancer
Nova Scotia Health AuthorityLead Sponsor
233 Previous Clinical Trials
80,065 Total Patients Enrolled
3 Trials studying Breast Cancer
186 Patients Enrolled for Breast Cancer
Eligibility Criteria
Age 18+ · Female Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You must be at least 18 years old to participate in this study.
Who else is applying?
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments